Laurus Labs profit more than doubles; acquisitions approved
In short
Laurus Labs said its September-quarter profit more than doubled and beat estimates on revenue and EBITDA too. The company also approved buying a Canadian biotech firm and a polymer products maker.
This looks positive for the company’s results and growth plans. The report does not say how much the deals cost or when they will close.
What the reporting says
Laurus Labs said its September-quarter profit more than doubled, beating estimates along with revenue and EBITDA, according to the publisher summary. The company also approved acquisitions of a Canadian biotech firm and a polymer products maker. The reporting does not give the profit figure, deal value, or closing timeline, so the size and timing of the acquisitions remain unknown.
Why it matters
Laurus Labs reported a September-quarter profit that more than doubled and beat estimates on revenue and EBITDA, according to the publisher summary. The company also approved acquisitions of a Canadian biotech firm and a polymer products maker. The reporting does not provide deal values or completion dates, so the financial scale of the acquisitions is not stated.